UK consensus statement on the use of plerixafor to facilitate autologous peripheral blood stem cell collection to support high-dose chemoradiotherapy for patients with malignancy-Reference-Cited by-同舟云学术

UK consensus statement on the use of plerixafor to facilitate autologous peripheral blood stem cell collection to support high-dose chemoradiotherapy for patients with malignancy

Published:2017-06-20 Issue:1 Volume:33 Page:46-59
ISSN:0733-2459
Container-title:Journal of Clinical Apheresis
language:en
Short-container-title:J Clin Apher

Author:

Douglas Kenneth W.¹^ORCID,Gilleece Maria²,Hayden Patrick³,Hunter Hannah⁴,Johnson Peter R. E.⁵,Kallmeyer Charlotte⁶,Malladi Ram K.⁷,Paneesha Shankara⁸,Pawson Rachel⁹,Quinn Michael¹⁰,Raj Kavita¹¹,Richardson Deborah¹²,Robinson Stephen¹³,Russell Nigel¹⁴,Snowden John¹⁵,Sureda Anna¹⁶,Tholouli Eleni¹⁷,Thomson Kirsty¹⁸,Watts Mike¹⁹,Wilson Keith M.²⁰

Affiliation:

1. Clinical Apheresis Unit; Beatson West of Scotland Cancer Centre; Glasgow United Kingdom

2. Yorkshire Blood and Marrow Transplant Programme; Leeds Teaching Hospitals; Leeds United Kingdom

3. Haematology Department; St James's Hospital; Dublin Ireland

4. Haematology Department, Derriford Hospital; Plymouth Hospitals NHS Trust; Plymouth United Kingdom

5. Department of Haematology; Western General Hospital; Edinburgh United Kingdom

6. Department of Haematology, Lincoln County Hospital; United Lincolnshire Hospitals NHS Trust; Lincoln, United Kingdom

7. Centre for Clinical Haematology; University Hospitals Birmingham; Birmingham United Kingdom

8. Department of Haematology; Heart of England NHS Foundation Trust; Birmingham United Kingdom

9. Tissue Services and Cell Banking; NHS Blood and Transplant; Bristol, United Kingdom

10. Department of Haematology; Belfast NHS Trust; Belfast, United Kingdom

11. Haematological Cancer Services; King's College Hospital NHS Foundation Trust; London United Kingdom

12. Department of Haematology; University Hospital Southampton; Southampton United Kingdom

13. Bristol Haematology Unit; University Hospitals Bristol; Bristol, United Kingdom

14. Clinical Haematology; Nottingham University Hospital; Nottingham United Kingdom

15. Department of Haematology, Sheffield Teaching Hospitals; Sheffield United Kingdom

16. Department of Haematology; Institut Catalá d'Oncologia; Barcelona Spain

17. HSC Transplant Services, Department of Haematology; Central Manchester University Hospitals; Manchester United Kingdom

18. Department of Clinical Haematology; University College Hospitals; London United Kingdom

19. Wolfson Cellular Therapies Unit; University College Hospitals; London United Kingdom

20. Department of Haematology; Cardiff & Vale University Health Board; Cardiff United Kingdom

Publisher

Wiley

Subject

Hematology,General Medicine

Reference47 articles.

1. Defining a therapeutic dose of peripheral blood stem cells;Bender;J Hematother.,1992

2. Peripheral blood progenitor cell mobilization for autologous and allogenic stem cell transplantation; guidelines of the American Society for Blood and Marrow Transplantation;Duong;Biol Blood Marrow Transplant.,2014

3. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation;Pusic;Biol Blood Marrow Transplant.,2008

4. Predictive factors for poor peripheral blood stem cell mobilization and peak CD34+ cell count to guide pre-emptive or immediate rescue mobilization;Sancho;Cytotherapy.,2012

5. Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma;Keating;Drugs.,2011

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Higher efficacy of Etoposide + Cytarabine Plus Pegfilgrastim in poorly mobilizing Multiple Myeloma and lymphoma Patients;Cytotherapy;2023-08

2. Stem cell mobilization in multiple myeloma: challenges, strategies, and current developments;Annals of Hematology;2023-03-22

3. The effect of preemptive use of plerixafor on stem cell mobilization in patients with lymphoma and multiple myeloma;Marmara Medical Journal;2023-01-31

4. Poor Mobilizers in Lymphoma but Not Myeloma Patients Had Significantly Poorer Progression-Free Survival after Autologous Stem Cell Transplantation: Results of a Large Retrospective, Single-Center Observational Study;Cancers;2023-01-18

5. Mobilization Strategies in Myeloma Patients Intended for Autologous Hematopoietic Cell Transplantation;Transfusion Medicine and Hemotherapy;2023